Skip to main content
Top
Published in: Digestive Diseases and Sciences 12/2008

01-12-2008 | Original Paper

A Glass of Water Immediately Increases Gastric pH in Healthy Subjects

Authors: George Karamanolis, Ioanna Theofanidou, Marina Yiasemidou, Evangelos Giannoulis, Konstantinos Triantafyllou, Spiros D. Ladas

Published in: Digestive Diseases and Sciences | Issue 12/2008

Login to get access

Abstract

Onset of action of antisecretory agents is of pivotal importance for patients with gastroesophageal reflux disease (GERD) treated “on-demand.” Aim To study the acute effect of acid-inhibiting drugs and water administration on gastric pH. Method A cross-over study was performed in 12 H. pylori (-), healthy subjects (6 men; mean age: 26 years). A single oral dose of the following agents was received with a wash-out period between each study: a glass of water (200 ml), antacid, ranitidine, omeprazole, esomeprazole, and rabeprazole. Gastric pH was recorded for 6 h after drug intake. Results Water increased gastric pH >4 in 10/12 subjects after 1 min. The time (median) needed to pH >4 was for: antacid 2 min, ranitidine 50 min, omeprazole 171 min, esomeprazole 151 min, and rabeprazole 175 min. Gastric pH >4 lasted for 3 min after water and for 12 min after antacids; it remained >4 until the end of recording in: 4/12 subjects with ranitidine, 11/12 with rabeprazole, and all with omeprazole and esomeprazole. Conclusion Water and antacid immediately increased gastric pH, while PPIs showed a delayed but prolonged effect compared to ranitidine.
Literature
3.
go back to reference Fass R, Fennerty MB, Vakil N (2001) Nonerosive reflux disease-current concepts and dilemmas. Am J Gastroenterol 96:303–314PubMed Fass R, Fennerty MB, Vakil N (2001) Nonerosive reflux disease-current concepts and dilemmas. Am J Gastroenterol 96:303–314PubMed
4.
5.
go back to reference Tytgat GNJ, Blum AL, Verlinden M (1995) Prognostic factors for relapse and maintenance treatment with cisapride in gastro-esophageal reflux disease. Aliment Pharmacol Ther 9:271–280PubMed Tytgat GNJ, Blum AL, Verlinden M (1995) Prognostic factors for relapse and maintenance treatment with cisapride in gastro-esophageal reflux disease. Aliment Pharmacol Ther 9:271–280PubMed
7.
go back to reference Hatlebakk JG, Berstad A (1996) Pharmacokinetic optimization in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinet 31:386–406PubMed Hatlebakk JG, Berstad A (1996) Pharmacokinetic optimization in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinet 31:386–406PubMed
8.
go back to reference Bell NJ, Burget D, Howden CW et al (1992) Appropriate acid suppression for management of gastro-oesophageal reflux disease. Digestion 51(Suppl 1):59–67PubMedCrossRef Bell NJ, Burget D, Howden CW et al (1992) Appropriate acid suppression for management of gastro-oesophageal reflux disease. Digestion 51(Suppl 1):59–67PubMedCrossRef
9.
go back to reference Hurlimann S, Abbuhl B, Inauen W et al (1994) Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 8:193–201PubMedCrossRef Hurlimann S, Abbuhl B, Inauen W et al (1994) Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 8:193–201PubMedCrossRef
11.
13.
go back to reference Robinson M (2001) New generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol 13(Suppl 1):S43–S47PubMed Robinson M (2001) New generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol 13(Suppl 1):S43–S47PubMed
14.
go back to reference Hedenstrom H, Alm C, Kraft M, Grahnen A (1997) Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers. Aliment Pharmacol Ther 11:1137–1141. doi:10.1046/j.1365-2036.1997.00264.x PubMedCrossRef Hedenstrom H, Alm C, Kraft M, Grahnen A (1997) Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers. Aliment Pharmacol Ther 11:1137–1141. doi:10.​1046/​j.​1365-2036.​1997.​00264.​x PubMedCrossRef
15.
go back to reference Chassany O, Bergmann JF, Simoneau G et al (1996) The comparative effects of single intravenous doses of cimetidine, ranitidine, famotidine, and omeprazole on intragastric pH. Curr Ther Res 57:159–169. doi:10.1016/S0011-393X(96)80121-4 CrossRef Chassany O, Bergmann JF, Simoneau G et al (1996) The comparative effects of single intravenous doses of cimetidine, ranitidine, famotidine, and omeprazole on intragastric pH. Curr Ther Res 57:159–169. doi:10.​1016/​S0011-393X(96)80121-4 CrossRef
18.
go back to reference Zacny J, Zamakhshary M, Skertis I, Veldhuyzen van Zanten S (2005) Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther 21:1299–1312. doi:10.1111/j.1365-2036.2005.02490.x PubMedCrossRef Zacny J, Zamakhshary M, Skertis I, Veldhuyzen van Zanten S (2005) Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther 21:1299–1312. doi:10.​1111/​j.​1365-2036.​2005.​02490.​x PubMedCrossRef
Metadata
Title
A Glass of Water Immediately Increases Gastric pH in Healthy Subjects
Authors
George Karamanolis
Ioanna Theofanidou
Marina Yiasemidou
Evangelos Giannoulis
Konstantinos Triantafyllou
Spiros D. Ladas
Publication date
01-12-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-008-0301-3

Other articles of this Issue 12/2008

Digestive Diseases and Sciences 12/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.